Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms

Histopathology

Volumn 61, Issue 2, 2012, Pages 170-177

  Hemminger, Jessica ^a   Iwenofu, O Hans ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Discovered on GIST1; Gastrointestinal stromal tumours; Non gastrointestinal stromal neoplasms

Indexed keywords

DOG1 PROTEIN; FORMALDEHYDE; PARAFFIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ACINAR CELL CARCINOMA; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ARTICLE; CANCER PATIENT; CHORDOMA; CLEAR CELL SARCOMA; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DESMOPLASTIC MELANOMA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EMBEDDING; ENDOMETRIOID CARCINOMA; EPITHELIOID SARCOMA; FIBROMYXOID SARCOMA; FIBROSARCOMA; FORMALIN FIXED PARAFFIN EMBEDDING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GRANULAR CELL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MELANOMA; NERVE TUMOR; NEURILEMOMA; NEUROFIBROMA; PATHOPHYSIOLOGY; PLEOMORPHIC UNDIFFERENTIATED SARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; SARCOMA; SPINDLE CELL CARCINOMA; STAINING; SYNOVIAL SARCOMA; TISSUE SECTION; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CARCINOMA, ACINAR CELL; CARCINOMA, ENDOMETRIOID; CHLORIDE CHANNELS; COLORECTAL NEOPLASMS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NEOPLASM PROTEINS; NERVE SHEATH NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84864389152     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04150.x     Document Type: Article

References (39)

1. Odze RD, Goldblum JR. Surgical pathology of the GI tract, liver, biliary tract, and pancreas, 2nd edn. Philadelphia: Saunders/Elsevier, Inc.; 2009; 681-693.
2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279; 577-580.
3. Heinrich MC, Corless C, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21; 4342-4349.
4. Hirota S, Ohashi A, Nishida T et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125; 660-667.
5. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299; 708-710.
6. Agaram NP, Wong GC, Guo T et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosom. Cancer 2008; 47; 853-859.
7. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumour: a randomized, double-blind, placebo-controlled trial. Lancet 2009; 373; 1097-1104.
8. Antonescu CR. Targeted therapies in the gastrointestinal stromal tumors. Semin. Diagn. Pathol. 2008; 25; 295-303.
9. Demetri GD, Von Mehren M, Banke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347; 472-480.
10. Demetri GD, Van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 2006; 368; 1329-1338.
11. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 2008; 26; 626-632.
12. Nielsen TO, West RB, Linn SC et al. Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002; 359; 1301-1307.
13. West RB, Corless CL, Chen X et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 2004; 165; 107-113.
14. Espinosa I, Lee CH, Kim MK et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am. J. Surg. Pathol. 2008; 32; 210-218.
15. Liegl B, Hornick JL, Corless CL et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors including unusual subtypes. Am. J. Surg. Pathol. 2009; 33; 437-446.
16. Wong NACS, Shelley-Fraser G. Specificity of DOG1 (K9 clone) and protein kinase C theta (clone 27) as immunohistochemical markers of gastrointestinal stromal tumour. Histopathology 2010; 57; 250-258.
17. Novelli M, Rossi S, Rodriguez-Justo M et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumors. Histopathology 2010; 57; 259-270.
18. Miettinen M, Wang Z-F, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors. A study of 1840 cases. Am. J. Surg. Pathol. 2009; 33; 1401-1408.
19. Lopes LF, West RB, Bacchi LM, Van de Rijn M, Bacchi CE. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): comparison between 2 different antibodies. Appl. Immunohistochem. Mol. Morphol. 2010; 18; 333-337.
20. Caputo A, Caci E, Ferrera L et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008; 322; 590-594.
21. Yang DY, Cho H, Koo JY et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008; 455; 1210-1215.
22. Schroeder BC, Cheng T, Jan YN, Jan LY. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 2008; 134; 1019-1029.
23. Hartzell C, Putzier I, Arreola J. Calcium-activated chloride channels. Annu. Rev. Physiol. 2005; 67; 719-758.
24. Huang X, Godfrey TE, Gooding WE, McCarty KS Jr, Gollin SM. Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and synteny to the 7F5 amplicon in murine oral carcinoma. Genes Chromosom. Cancer 2006; 45; 1058-1069.
25. Schwab M. Amplification of oncogenes in human cancer cells. Bioessays 1998; 20; 473-479.
26. Katoh M, Katoh M. FLJ10261 gene, located within the CCND1-EMS1 locus on human chromosome 11q13, encodes the eight-transmembrane protein homologous to C12orf3, C11orf25and FLJ34272 gene products. Int. J. Oncol. 2003; 22; 1375-1381.
27. Carles A, Millon R, Cromer A et al. Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene 2006; 25; 1821-1831.
28. Eggermont J. Calcium-activated chloride channels: (un)known, (un)loved? Proc. Am. Thorac. Soc. 2004; 1; 22-27.
29. 2+ -activated Cl - channels - homing in on an elusive channel species. Prog. Neurobiol. 2000; 60; 247-289.
30. Rock JR, Harfe BD. Expression of TMEM16 paralogs during murine embryogenesis. Dev. Dyn. 2008; 237; 2566-2574.
31. Ardeleanu C, Arsene D, Hinescu M et al. Pancreatic expression of DOG1: a novel gastrointestinal stromal tumor (GIST) biomarker. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 413-418.
32. Chenevert J, Duvvuri U, Kim JH, Seethala RR. DOG1: a novel marker of salivary acinar differentiation. Mod. Pathol. 2011; 91; 276A.
33. Abdel-Hadi M, Bessa SS, Hamam SM. Evaluation of the novel monoclonal antibody against DOG1 as a diagnostic marker for gastrointestinal stromal tumors. J. Egypt Natl Canc Inst. 2009; 21; 237-247.
34. Parfitt JR, Rodriguez-Justo M, Feakins R, Novelli MR. Gastrointestinal Kaposi's sarcoma: CD117 expression and the potential for misdiagnosis as gastrointestinal stromal tumour. Histopathology 2008; 52; 816-823.
35. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J. Pathol. 2004; 202; 430-438.
36. Medeiros F, Corless CL, Duensing A et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am. J. Surg. Pathol. 2004; 28; 889-894.
37. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol. 1998; 1; 728-734.
38. Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol. 2008; 26; 5360-5367.
39. Lee C-H, Liang C-W, Espinosa I. The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology - the GIST of it. Adv. Anat. Pathol. 2010; 17; 222-232.